BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24169824)

  • 1. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
    Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
    Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
    Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
    Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
    Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
    Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
    Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
    Kortylewski M; Moreira D
    Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
    Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
    Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
    Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
    Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.
    Nechaev S; Gao C; Moreira D; Swiderski P; Jozwiak A; Kowolik CM; Zhou J; Armstrong B; Raubitschek A; Rossi JJ; Kortylewski M
    J Control Release; 2013 Sep; 170(3):307-15. PubMed ID: 23777886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.
    Herrmann A; Kortylewski M; Kujawski M; Zhang C; Reckamp K; Armstrong B; Wang L; Kowolik C; Deng J; Figlin R; Yu H
    Cancer Res; 2010 Oct; 70(19):7455-64. PubMed ID: 20841481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9-Targeted SiRNA Delivery In Vivo.
    Hossain DM; Moreira D; Zhang Q; Nechaev S; Swiderski P; Kortylewski M
    Methods Mol Biol; 2016; 1364():183-96. PubMed ID: 26472451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted silencing of genes related to acute monocytic leukaemia by CpG(B)-MLAA-34 siRNA conjugates.
    Huang B; He A; Zhang P; Ma X; Yang Y; Wang J; Wang J; Zhang W
    J Drug Target; 2020 Jun; 28(5):516-524. PubMed ID: 31718329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 is critical for glioma stem cell maintenance and targeting.
    Herrmann A; Cherryholmes G; Schroeder A; Phallen J; Alizadeh D; Xin H; Wang T; Lee H; Lahtz C; Swiderski P; Armstrong B; Kowolik C; Gallia GL; Lim M; Brown C; Badie B; Forman S; Kortylewski M; Jove R; Yu H
    Cancer Res; 2014 Sep; 74(18):5218-28. PubMed ID: 25047528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local CpG-
    Zhang C; Huang R; Ren L; Song J; Kortylewski M; Swiderski P; Forman S; Yu H
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.
    Kortylewski M; Kujawski M; Herrmann A; Yang C; Wang L; Liu Y; Salcedo R; Yu H
    Cancer Res; 2009 Mar; 69(6):2497-505. PubMed ID: 19258507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.
    Kortylewski M; Swiderski P; Herrmann A; Wang L; Kowolik C; Kujawski M; Lee H; Scuto A; Liu Y; Yang C; Deng J; Soifer HS; Raubitschek A; Forman S; Rossi JJ; Pardoll DM; Jove R; Yu H
    Nat Biotechnol; 2009 Oct; 27(10):925-32. PubMed ID: 19749770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
    Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q
    Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
    Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
    J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
    Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
    Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3: the "Achilles" heel for AML?
    Rezvani K; Barrett J
    Blood; 2014 Jan; 123(1):1-2. PubMed ID: 24385491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.